ClinicalTrials.gg

Program

calcipotriene

Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.

Its studies are mostly in Psoriasis · Alopecia Areata, led by 10 companies.

Furthest: phase 4, since Sep 15, 200537 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharma220 open or runningphase 4since Sep 15, 2005Sep 15, 2005none ahead
MC2 Therapeutics50 open or runningphase 3since Oct 9, 2017Oct 9, 2017none ahead
Almirall20 open or runningphase 3since Nov 11, 2015Nov 11, 2015none ahead
Mayne Pharma International Pty20 open or runningphase 1since Mar 15, 2012Mar 15, 2012none ahead
Abbott10 open or runningphase 3since Dec 12, 2007Dec 12, 2007none ahead
Egymedicalpedia10 open or runningno phasesince Jun 23, 2023Jun 23, 2023none ahead
GlaxoSmithKline10 open or runningphase 3since Jun 6, 2010Jun 6, 2010none ahead
Glenmark Pharmaceuticals Ltd. India10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead
Huadong Medicine10 open or runningphase 3since Dec 11, 2025Dec 11, 2025none ahead
Tolmar10 open or runningphase 1since Apr 6, 2017Apr 6, 2017none ahead

Also a collaborator on its studies: bioskin-gmbh.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 23 studies since Sep 15, 2005.

  1. Mar 12, 2015Phase 2 study in Psoriasis VulgarisLEO Pharma · NCT02387853 · 117 enrolled · United States, Netherlands, Poland and more
  2. Nov 11, 2015Almirall's first study: phase 3 study in Nail PsoriasisNew to AlmirallAlmirall · NCT02606760 · 378 enrolled · Bulgaria, Czechia, Germany and more
  3. Mar 9, 2017Phase 3 study in Nail PsoriasisAlmirall · NCT03079973 · United States
  4. Apr 6, 2017Tolmar's first study: phase 1 study in Scalp PsoriasisNew to TolmarTolmar · NCT03122353 · 699 enrolled · United States
  5. Oct 9, 2017MC2 Therapeutics's first study: phase 3 study in Psoriasis VulgarisNew to MC2 TherapeuticsMC2 Therapeutics · NCT03308799 · 794 enrolled · United States
  6. Nov 1, 2017Glenmark Pharmaceuticals Ltd. India's first study: phase 3 study in Scalp PsoriasisNew to Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals Ltd. India · NCT03331523 · 643 enrolled · United States
  7. Feb 20, 2018Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03462927 · 63 enrolled · United States
  8. Nov 13, 2018Phase 1 study in VasoconstrictionMC2 Therapeutics · NCT03758365 · 36 enrolled · France
  9. Jan 10, 2019Phase 3 study in Psoriasis VulgarisMC2 Therapeutics · NCT03802344 · 498 enrolled · Czechia, Germany
  10. Jan 11, 2019Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03819218 · 7 enrolled · Czechia, Germany
  11. Mar 29, 2019Phase 1 study in Psoriasis VulgarisLEO Pharma · NCT03898583 · 15 enrolled · Germany
  12. Jun 16, 2023Phase 3 study in Stable Plaque PsoriasisLEO Pharma · NCT05919082 · 604 enrolled · China
  13. Jun 23, 2023Egymedicalpedia's first study: no phase study in Alopecia AreataNew to EgymedicalpediaEgymedicalpedia · NCT05954104 · 80 enrolled · Egypt
  14. Dec 11, 2025Huadong Medicine's first study: phase 3 study in Plaque PsoriasisNew to Huadong MedicineHuadong Medicine · NCT07357831 · 539 enrolled · China

TargetBeta

VDR →read by rule
“Vitamin D receptor agonist”ChEMBL 37, by rule

Other programs on VDR

ProgramCompanyFurthest phaseStudies
Modified-release Calcifediol CapsuleruleOPKO Healthphase 310

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07357831Plaque Psoriasis · China3CompletedHuadong MedicineAug 6, 2026539
NCT05954104Alopecia Areata · Egypt–CompletedEgymedicalpediaOct 1, 202380
NCT05919082Stable Plaque Psoriasis · China3CompletedLEO PharmaFeb 23, 2024604
NCT03898583Psoriasis Vulgaris · Germany1CompletedLEO PharmaOct 29, 201915
NCT03819218Psoriasis Vulgaris · Czechia, Germany2TerminatedMC2 TherapeuticsDec 11, 20207
NCT03802344Psoriasis Vulgaris · Czechia, Germany3CompletedMC2 TherapeuticsOct 2, 2019498
NCT03758365Vasoconstriction · France1CompletedMC2 TherapeuticsNov 23, 201836
NCT03462927Psoriasis Vulgaris · United States2CompletedMC2 TherapeuticsAug 4, 201863
NCT03331523Scalp Psoriasis · United States3CompletedGlenmark Pharmaceuticals Ltd. IndiaOct 25, 2018643
NCT03308799Psoriasis Vulgaris · United States3CompletedMC2 TherapeuticsJun 8, 2018794
NCT03122353Scalp Psoriasis · United States1CompletedTolmarNov 15, 2017699
NCT03079973Nail Psoriasis · United States3WithdrawnAlmirallJul 20180
NCT02606760Nail Psoriasis · Bulgaria, Czechia, Germany and more3CompletedAlmirallFeb 8, 2017378
NCT02387853Psoriasis Vulgaris · United States, Netherlands, Poland and more2CompletedLEO PharmaMar 28, 2018117
NCT01935869Psoriasis Vulgaris · France1CompletedLEO PharmaNov 2013224
NCT01866163Psoriasis Vulgaris · United States3CompletedLEO PharmaOct 2013426
NCT01600222Psoriasis Vulgaris · Canada2CompletedLEO PharmaMay 201337
NCT01582932Psoriasis · United States1CompletedMayne Pharma International PtyAug 201836
NCT01563068Psoriasis · United States1CompletedMayne Pharma International PtyAug 201518
NCT01536938Psoriasis Vulgaris · United States2CompletedLEO PharmaSep 2012303
NCT01536886Psoriasis Vulgaris · United States2CompletedLEO PharmaSep 2012376
NCT01188928Psoriasis Vulgaris · United States3CompletedLEO PharmaMar 20111,152
NCT01139580Psoriasis · United States3CompletedGlaxoSmithKlineDec 2010363
NCT00817219Psoriasis Vulgaris · United States2CompletedLEO PharmaDec 201133
NCT00704262Psoriasis Vulgaris · United States, Canada, Germany and more2CompletedLEO PharmaDec 200933
NCT00691002Psoriasis Vulgaris · Croatia, Germany, Poland and more3CompletedLEO PharmaJan 20101,245
NCT00670241Psoriasis Vulgaris · Canada3CompletedLEO PharmaFeb 2009458
NCT00640822Psoriasis Vulgaris · Canada, France, United Kingdom3CompletedLEO PharmaJun 2009782
NCT00574249Psoriasis · Austria, Belgium, Czech Republic and more3CompletedAbbottOct 2008730
NCT00279162Psoriasis · United States3CompletedLEO Pharma160
NCT00263718Psoriasis Vulgaris · Canada, Germany, Ireland and more2CompletedLEO Pharma360
NCT00248456Psoriasis Vulgaris · China4CompletedLEO Pharma320
NCT00243464Psoriasis of Scalp · Belgium, Canada, Denmark and more3CompletedLEO Pharma300
NCT00216892Psoriasis Vulgaris · Belgium, Canada, France and more4CompletedLEO Pharma1,032
NCT00216879Psoriasis of Scalp · Canada, Denmark, France and more3CompletedLEO Pharma800
NCT00216840Psoriasis of Scalp · Belgium, Canada, Finland and more3CompletedLEO Pharma1,350
NCT00216827Psoriasis of Scalp · Canada, Denmark, France and more3CompletedLEO Pharma1,485

How it is read

Names in the registry

  • “LEO 90100”, 7 entries
  • “MC2-01 cream”, 4 entries
  • “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
  • “Calcipotriol plus hydrocortisone (LEO 80190)”, 2 entries
  • “MC2-01 Cream”, 2 entries

Codes read as this program: P3073.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.